MX2009011214A - Uso de 4-ciclopropilmetoxi-n-(3,5-dicloro-1-oxido-4-piridin-4-il)- 5-(metoxi)piridin-2-carboxamida para el tratamiento de los traumatismos craneales. - Google Patents

Uso de 4-ciclopropilmetoxi-n-(3,5-dicloro-1-oxido-4-piridin-4-il)- 5-(metoxi)piridin-2-carboxamida para el tratamiento de los traumatismos craneales.

Info

Publication number
MX2009011214A
MX2009011214A MX2009011214A MX2009011214A MX2009011214A MX 2009011214 A MX2009011214 A MX 2009011214A MX 2009011214 A MX2009011214 A MX 2009011214A MX 2009011214 A MX2009011214 A MX 2009011214A MX 2009011214 A MX2009011214 A MX 2009011214A
Authority
MX
Mexico
Prior art keywords
oxidopyridin
cyclopropylmethoxy
carboxamide
dichloro
pyridine
Prior art date
Application number
MX2009011214A
Other languages
English (en)
Inventor
Philippe Delay-Goyet
Corinne Perron
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38819821&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2009011214(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of MX2009011214A publication Critical patent/MX2009011214A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)

Abstract

La invención se refiere al uso de 4-ciclopropilmetoxi-N-(3,5-diclo ro-1-óxido-pirimidin-4-il)-5-(metoxi)piridin-2-carboxamida para la preparación de un medicamento destinado al tratamiento de traumatismos cerebrales.
MX2009011214A 2007-04-19 2008-04-16 Uso de 4-ciclopropilmetoxi-n-(3,5-dicloro-1-oxido-4-piridin-4-il)- 5-(metoxi)piridin-2-carboxamida para el tratamiento de los traumatismos craneales. MX2009011214A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0702852A FR2915099B1 (fr) 2007-04-19 2007-04-19 Utilisation du 4-cyclopropylmethoxy-n-(3,5-dichloro-1-oxydo- pyridin-4-yl)-5-(methoxy)pyridine-2-carboxamide pour le traitement des traumatismes craniens
PCT/FR2008/000531 WO2008145838A2 (fr) 2007-04-19 2008-04-16 Utilisation du 4-cyclopropylmethoxy-n-(3,5-dichloro-1-oxydo-4- pyridin-4-yl)-5-(methoxy)pyridine-2-carboxamide pour le traitement des traumatismes craniens

Publications (1)

Publication Number Publication Date
MX2009011214A true MX2009011214A (es) 2009-11-02

Family

ID=38819821

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009011214A MX2009011214A (es) 2007-04-19 2008-04-16 Uso de 4-ciclopropilmetoxi-n-(3,5-dicloro-1-oxido-4-piridin-4-il)- 5-(metoxi)piridin-2-carboxamida para el tratamiento de los traumatismos craneales.

Country Status (34)

Country Link
US (1) US9393236B2 (es)
EP (1) EP2146713B1 (es)
JP (1) JP5386476B2 (es)
KR (1) KR101460828B1 (es)
CN (1) CN101663036B (es)
AR (1) AR066105A1 (es)
AT (1) ATE532513T1 (es)
AU (1) AU2008257319B2 (es)
BR (1) BRPI0810423A2 (es)
CA (1) CA2684171C (es)
CL (1) CL2008001135A1 (es)
CO (1) CO6140028A2 (es)
CY (1) CY1112282T1 (es)
DK (1) DK2146713T3 (es)
EA (1) EA015503B1 (es)
ES (1) ES2376023T3 (es)
FR (1) FR2915099B1 (es)
HK (1) HK1141724A1 (es)
HR (1) HRP20120130T1 (es)
IL (1) IL201447A (es)
JO (1) JO2861B1 (es)
MA (1) MA31368B1 (es)
ME (2) ME00938B (es)
MX (1) MX2009011214A (es)
MY (1) MY147207A (es)
NZ (1) NZ580484A (es)
PA (1) PA8776701A1 (es)
PL (1) PL2146713T3 (es)
PT (1) PT2146713E (es)
RS (1) RS52130B (es)
SI (1) SI2146713T1 (es)
TW (1) TWI423800B (es)
UY (1) UY31034A1 (es)
WO (1) WO2008145838A2 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016500094A (ja) * 2012-11-28 2016-01-07 サノフイ ４−（シクロプロピルメトキシ）−ｎ−（３，５−ジクロロ−１−オキシドピリジン−４−イル）−５−メトキシピリジン−２−カルボキサミドの結晶形態の製造方法およびその結晶形態

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1273326A (en) * 1917-08-22 1918-07-23 George H Bugenhagen Transmission mechanism.
US4193926A (en) * 1974-03-20 1980-03-18 Schering Aktiengesellschaft 4-(Polyalkoxy phenyl)-2-pyrrolidones
PT711282E (pt) * 1993-07-28 2002-11-29 Aventis Pharma Ltd Compostos inibidores de pde iv e de fnt
GB9401460D0 (en) * 1994-01-26 1994-03-23 Rhone Poulenc Rorer Ltd Compositions of matter
GB9507297D0 (en) * 1995-04-07 1995-05-31 Rh Ne Poulenc Rorer Limited New composition of matter
US6177077B1 (en) * 1999-02-24 2001-01-23 Edward L. Tobinick TNT inhibitors for the treatment of neurological disorders
CA2376076A1 (en) * 1999-06-07 2000-12-14 Warner-Lambert Company Tricyclic analgesics
JP2003519139A (ja) * 1999-12-23 2003-06-17 アイコス コーポレイション 環状ａｍｐ−特異的ホスホジエステラーゼ阻害剤
US20030069169A1 (en) * 2001-03-02 2003-04-10 Macor John E. Co-administration of melanocortin receptor agonist and phosphodiesterase inhibitor for treatment of cyclic-AMP associated disorders
EP1519922A1 (en) 2002-07-02 2005-04-06 Merck Frosst Canada & Co. Di-aryl-substituted ethane pyridone pde4 inhibitors
US20060083714A1 (en) * 2003-01-27 2006-04-20 Warner James M Combination of a pde iv inhibitor and a tnf-alpha antagonist
WO2005034870A2 (en) 2003-10-07 2005-04-21 Renovis, Inc. Amide compounds and ion channel ligands and uses thereof
EP1888528A2 (en) * 2005-06-10 2008-02-20 Memory Pharmaceuticals Corporation Phosphodiesterase 4 inhibitors
US20070021451A1 (en) * 2005-07-20 2007-01-25 Hamamatsu University School Of Medicine Method for preventing or treating neurologic damage after spinal cord injury
FR2915098B1 (fr) 2007-04-19 2009-06-05 Sanofi Aventis Sa Utilisation du 4-cyclopropylmethoxy-n-(3,5-dichloro-1-oxydo- pyridin-4-yl)-5-(methoxy)pyridine-2-carboxamide pour le traitement des traumatismes de la moelle epiniere

Also Published As

Publication number Publication date
IL201447A0 (en) 2010-05-31
CL2008001135A1 (es) 2009-01-16
ME01273B (me) 2013-06-20
ES2376023T3 (es) 2012-03-08
KR20090130058A (ko) 2009-12-17
TW200914009A (en) 2009-04-01
RS52130B (en) 2012-08-31
MA31368B1 (fr) 2010-05-03
FR2915099B1 (fr) 2009-06-05
AR066105A1 (es) 2009-07-22
JP2010524903A (ja) 2010-07-22
HRP20120130T1 (hr) 2012-03-31
ME00938B (me) 2012-06-20
CY1112282T1 (el) 2015-12-09
MY147207A (en) 2012-11-14
CO6140028A2 (es) 2010-03-19
JO2861B1 (en) 2015-03-15
BRPI0810423A2 (pt) 2014-10-14
SI2146713T1 (sl) 2012-03-30
HK1141724A1 (es) 2010-11-19
CN101663036B (zh) 2012-06-20
EA200970968A1 (ru) 2010-02-26
WO2008145838A3 (fr) 2009-03-26
CA2684171C (fr) 2015-12-01
IL201447A (en) 2013-07-31
EP2146713A2 (fr) 2010-01-27
TWI423800B (zh) 2014-01-21
ATE532513T1 (de) 2011-11-15
CA2684171A1 (fr) 2008-12-04
JP5386476B2 (ja) 2014-01-15
EP2146713B1 (fr) 2011-11-09
DK2146713T3 (da) 2012-03-05
UY31034A1 (es) 2008-11-28
AU2008257319B2 (en) 2013-07-25
AU2008257319A1 (en) 2008-12-04
US9393236B2 (en) 2016-07-19
WO2008145838A2 (fr) 2008-12-04
KR101460828B1 (ko) 2014-11-11
PT2146713E (pt) 2012-02-07
PA8776701A1 (es) 2008-11-19
US20100130553A1 (en) 2010-05-27
PL2146713T3 (pl) 2012-04-30
NZ580484A (en) 2011-06-30
EA015503B1 (ru) 2011-08-30
CN101663036A (zh) 2010-03-03
FR2915099A1 (fr) 2008-10-24

Similar Documents

Publication Publication Date Title
NZ610034A (en) Prevention of adverse effects caused by cd3 specific binding domains
MX2011007930A (es) Conjugados de insulina cristalina.
MY148723A (en) Use of pinolenic acid for the treatment of obesity
MY152279A (en) Immediate release pharmaceutical compositions comprising oxycodone and naloxone
MY146112A (en) Long-term feed - cancer patient
MX2008013714A (es) Elastomeros de silicona que contienen antisepticos.
MX2010006204A (es) Derivados de oxindol 5,6-disubstituidos y el uso de los mismos para el tratamiento de enfermedades dependientes de la vasopresina.
ZA201001262B (en) Interval therapy for the treatment of tinnitus
MX2010006206A (es) Derivados de oxindol substituidos por 5-halogeno y el uso de los mismos para el tratamiento de enfermedades dependientes de la vasopresina.
MY150931A (en) Substituted oxazolidinones and their use
IL196745A (en) Idabanon for use in providing mucosal pathways to treat disease
MY185134A (en) 6-substituted phenoxychroman carboxylic acis derivatives
GB0715790D0 (en) Drug combination for the treatment of sialorrhoea
MY146657A (en) Use of 4-cyclopropylmethoxy-n- (3,5-dichloro-1-oxido-pyridin-4-yl)-5-(methoxy) pyridine-2-carboxamide for the treatment of spinal cord traumas
ZA201005306B (en) 5-o-substituted 3-n-phenyl-1,3,4-oxadiazolones for medical use
GB0710277D0 (en) Use of antivirals in the treatment of medical disorders
MX2009011214A (es) Uso de 4-ciclopropilmetoxi-n-(3,5-dicloro-1-oxido-4-piridin-4-il)- 5-(metoxi)piridin-2-carboxamida para el tratamiento de los traumatismos craneales.
MY148092A (en) Use of 4-cyclopropylmethoxy-n-(3,5-dichloro-1-oxidopyridin-4-yl)-5-(methoxy)pyridine-2-carboxamide for the treatment of motor disorders related to parkinson's disease
PL2036575T3 (pl) Kompozycje farmaceutyczne do stosowania doustnie w leczeniu pacjentów dotkniętych otyłością
EP2425829A4 (en) SOLUBLE PHARMACEUTICAL FORMS OF N, N'-DIAMINODIPHENYLSULPHONE FOR OPTIMAL USE IN THE TREATMENT OF VARIOUS ILLNESSES
UA106224C2 (en) Crystalline insulin-conjugates
TN2010000463A1 (en) Compositions and methods for preparing and using same
UA29783U (en) Orthodontic device
UA85522C2 (ru) N-стеароилетаноламин в качестве лекарственного средства в сопроводительной противоопухолевой терапии

Legal Events

Date Code Title Description
FG Grant or registration